Basilea Pharmaceutica

BSLN.SWPhase 3

Basel, SwitzerlandFounded 2000basilea.com

Founded in 2000, Basilea Pharmaceutica is a Swiss biopharma company dedicated to addressing the critical global health challenge of antimicrobial resistance. The company has successfully transitioned to a commercial-stage entity with two approved and marketed products, Cresemba and Zevtera, generating revenue and operating profit. With a focused pipeline, strategic collaborations like its BARDA partnership, and a commitment to ESG principles, Basilea is strategically positioned for growth in the specialized anti-infectives market.

Market Cap

$811.6M

Founded

2000

Employees

~150

Focus

Small Molecules

BSLN.SW · Stock Price

USD 52.10+15.64 (+42.90%)

Historical price data

AI Company Overview

Technology Platform

Specialized expertise in the research, development, and commercialization of novel anti-infective drugs for severe bacterial and fungal infections, with a focus on addressing antimicrobial resistance.

Pipeline Snapshot

54 drugs in pipeline, 17 in Phase 3

Drug	Indication	Stage
alitretinoin	Hand Dermatoses	Phase 3
Ceftobiprole medocaril + Vancomycin	Skin Diseases, Infectious	Phase 3
ceftobiprole medocaril + vancomycin+aztreonam	Acute Bacterial Skin and Skin Structure Infections	Phase 3
alitretinoin	Hand Dermatoses	Phase 3
ceftobiprole plus placebo + linezolid plus ceftazidime	Pneumonia	Phase 3

Funding History

Total raised: $375M

PIPE$75MUndisclosedNov 15, 2021

Debt$100MUndisclosedAug 15, 2015

IPO$200MUndisclosedMar 15, 2000

Opportunities

Significant growth opportunity lies in the global expansion and deeper market penetration of its two approved drugs, Cresemba and Zevtera, particularly in high-growth regions like Asia Pacific.

The development of ceftibuten-ledaborbactam, supported by BARDA, targets the critical unmet need of carbapenem-resistant infections, representing a major future value driver.

Increasing global focus and potential new economic models for anti-infectives (like subscription/pull incentives) could improve the long-term commercial landscape for its pipeline.

Risk Factors

Key risks include the challenging commercial environment for antibiotics (stewardship, pricing), clinical development risks for its pipeline candidates, and dependence on the continued sales success of its two main products for financial stability.

The company also faces competition from larger pharmaceutical firms and the constant scientific challenge of pathogens developing resistance.

Competitive Landscape

Basilea competes with large pharma anti-infective divisions (e.g., Pfizer, Merck) and specialized biotechs in a tough market. Its differentiation is its pure-play focus on anti-infectives, a balanced portfolio spanning antifungals and antibiotics, and a commercial-stage profile with global reach. Success depends on out-executing competitors in commercialization and advancing a differentiated pipeline.

Publications

Patents

Pipeline